Nascent Biotech INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OTC.Pink
Douglas John Karas, a director of Nascent Biotech Inc., acquired 50,000 shares of common stock at $0.10 per share on June 30, 2024, as part of his employment contract.
OTC.Pink
Lowell Thomas Holden, CFO of Nascent Biotech Inc., acquired 96,000 shares of common stock at $0.09 per share on June 30, 2024, as part of his employment contract.
OTC.Pink
Nascent Biotech's CEO, Sean Carrick, acquired 192,000 shares of common stock on June 30, 2024, as part of his employment contract.
OTC.Pink
Lowell Thomas Holden, CFO of Nascent Biotech Inc., reports the acquisition of 112,500 shares of common stock on March 31, 2024, as part of his employment contract.
OTC.Pink
Nascent Biotech's President and CEO, Sean Carrick, acquired 225,000 shares of common stock at a price of $0.1845 per share on March 31, 2024, as part of his employment contract.
OTC.Pink
Director Douglas Karas acquired 27,100 shares of Nascent Biotech Inc. (NBIO) at a price of $0.1845 on March 31, 2024, as part of his employment contract.
OTC.Pink
Nascent Biotech's CEO, Sean Carrick, acquired 239,300 shares of common stock at $0.17 per share on December 29, 2023, as part of his employment contract.
OTC.Pink
Lowell Thomas Holden, CFO of Nascent Biotech Inc., acquired 119,650 shares of common stock as part of his employment contract on December 29, 2023.
OTC.Pink
Director Douglas Karas acquired 28,935 shares of Nascent Biotech Inc. common stock on December 29, 2023, as part of his employment contract.